Disease Risk Factor Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Disease Risk Factor Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bristol Myers Squibb Co.
Tissue and gene-selective modulation is possible with selective LXR modulators
October 17th, 2004
Researchers report raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. Scientists writing in the Journal of Lipid Research report, "Liver X receptors (LXRs) are ligand-activated transcription factors that belong to the nuclear receptor superfamily. LXRs activate transcription of a spectrum of genes that regulate reverse cholesterol transport, including the ATP binding cassette transporter A1 (ABCA1), and raise HDL cholesterol (HDL-C) levels. However, LXR agonists also induce genes that stimulate lipogenesis, including the sterol response element binding protein (SREBP1-c) and fatty acid synthetase...
Source: Disease Risk Factor Week (2004-10-17)
|
